We are live on !
Find out more
General Catalyst Group Management Portfolio holdings
AUM
$189M
Turnover
37.5%
1-Year Est. Return
10.96%
This Fund
S&P 500
This Quarter Est. Return
+19.18%
1 Year Est. Return
-10.96%
3 Year Est. Return
+160.84%
5 Year Est. Return
+123.29%
10 Year Est. Return
–
AUM
$189M
AUM Growth
+$4.95M
(+2.7%)
Cap. Flow
-$22.9M
Cap. Flow % of AUM
Cap. Flow %
-12.15%
Top 10 Holdings %
Top 10 Hldgs %
98.96%
Holding
16
New
4
Increased
3
Reduced
–
Closed
2
Avg Time Held
0.7
years
Top 10 Avg Time Held
0.8
years
Top 20 Avg Time Held
0.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PBLS
Parabilis Medicines Inc
PBLS
|
+$44.2M |
| 2 |
Odyssey Therapeutics
ODTX
|
+$14.2M |
| 3 |
DoorDash
DASH
|
+$471K |
| 4 |
Carvana
CVNA
|
+$457K |
| 5 |
Meta Platforms (Facebook)
META
|
+$405K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Samsara
IOT
|
+$63.4M |
| 2 |
GitLab
GTLB
|
+$19.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 79.4% |
| 2 | Consumer Discretionary | 19.35% |
| 3 | Financials | 0.71% |
| 4 | Communication Services | 0.39% |
| 5 | Technology | 0.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
ArriVent BioPharma
AVBP
$759M
| $51.9M | 27.55% |
1,494,786
| – | – |
2024 Q1
9 quarters
|
|
|
PBLS
2
Parabilis Medicines Inc
PBLS
$3.27B
| $43.8M | 23.24% |
+1,600,937
| New | +$44.2M |
2026 Q2
0 quarters
|
|
3
Maplebear
CART
$14.3B
| $33.7M | 17.85% |
710,711
| – | – |
2023 Q3
11 quarters
|
|
4
Maze Therapeutics
MAZE
$1.76B
| $30.9M | 16.4% |
1,035,910
| – | – |
2025 Q1
5 quarters
|
|
|
5
Odyssey Therapeutics
ODTX
$937M
| $15.2M | 8.04% |
+810,272
| New | +$14.2M |
2026 Q2
0 quarters
|
|
6
Eikon Therapeutics
EIKN
$300M
| $3.98M | 2.11% |
305,233
| – | – |
2026 Q1
1 quarter
|
|
7
Fractyl Health
GUTS
$11.7M
| $3.88M | 2.06% |
407,016
| – | – |
2025 Q2
4 quarters
|
|
8
Ethos Technologies Inc
LIFE
$2.76B
| $1.35M | 0.71% |
74,179
| – | – |
2026 Q1
1 quarter
|
|
9
Coupang
CPNG
$25B
| $950K | 0.5% |
54,677
+18,000
| +49% | +$325K |
2026 Q1
1 quarter
|
|
10
Amazon
AMZN
$2.73T
| $925K | 0.49% |
3,882
+1,300
| +50% | +$326K |
2026 Q1
1 quarter
|
|
|
11
Meta Platforms (Facebook)
META
$1.61T
| $744K | 0.39% |
1,320
+662
| +101% | +$405K |
2026 Q1
1 quarter
|
|
|
12
DoorDash
DASH
$73.9B
| $526K | 0.28% |
+2,850
| New | +$471K |
2026 Q2
0 quarters
|
|
|
13
Carvana
CVNA
$65.2B
| $426K | 0.23% |
+6,465
| New | +$457K |
2026 Q2
0 quarters
|
|
14
Figma
FIG
$12.2B
| $269K | 0.14% |
14,845
| – | – |
2025 Q3
3 quarters
|
|
|
15
GitLab
GTLB
$9.47B
| – | – |
-921,405
| Closed | -$19.9M | – |
|
|
16
Samsara
IOT
$25.5B
| – | – |
-2,000,000
| Closed | -$63.4M | – |
|
Similar funds
ICM
SHC
General Catalyst Group Management's Q2 2026 Portfolio in Review
As of Q2 2026, General Catalyst Group Management held 16 positions worth $189M, up 2.7% from $184M the previous quarter. Its ten largest holdings account for 99% of the portfolio.
General Catalyst Group Management withdrew a net $22.9M in Q2 2026, closing 2 positions. Its most notable exit was Samsara, an estimated $63.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 39% a quarter earlier, followed by Consumer Discretionary and Financials.
Against the trend, General Catalyst Group Management opened a new position in Parabilis Medicines Inc worth $43.8M.
- General Catalyst Group Management's largest Q2 2026 buy was Parabilis Medicines Inc: 1,600,937 shares worth $43.8M.
- General Catalyst Group Management added most to Meta Platforms (Facebook) in Q2 2026, an estimated $405K increase.
- General Catalyst Group Management fully exited Samsara in Q2 2026, selling an estimated $63.4M.
- General Catalyst Group Management's ten largest holdings make up 99% of its $189M portfolio in Q2 2026.
- General Catalyst Group Management opened 4 new positions and closed 2 in Q2 2026.
- General Catalyst Group Management's portfolio value rose 2.7% quarter-over-quarter to $189M.
Based on General Catalyst Group Management's 13F filing for Q2 2026, filed 17 Aug 2026.